Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0Y7KH
|
||||
Former ID |
DNC005341
|
||||
Drug Name |
DEGARELIX
|
||||
Drug Type |
Small molecular drug
|
||||
Structure |
Download2D MOL |
||||
Formula |
C82H103ClN18O16
|
||||
InChI |
InChI=1S/C82H103ClN18O16/c1-45(2)35-60(72(107)92-59(16-9-10-33-87-46(3)4)80(115)101-34-12-17-68(101)79(114)88-47(5)70(84)105)93-74(109)63(38-51-23-30-58(31-24-51)91-81(85)116)95-76(111)64(39-50-21-28-57(29-22-50)90-71(106)66-42-69(104)100-82(117)99-66)97-78(113)67(44-102)98-77(112)65(41-53-13-11-32-86-43-53)96-75(110)62(37-49-19-26-56(83)27-20-49)94-73(108)61(89-48(6)103)40-52-18-25-54-14-7-8-15-55(54)36-52/h7-8,11,13-15,18-32,36,43,45-47,59-68,87,102H,9-10,12,16-17,33-35,37-42,44H2,1-6H3,(H2,84,105)(H,88,114)(H,89,103)(H,90,106)(H,92,107)(H,93,109)(H,94,108)(H,95,111)(H,96,110)(H,97,113)(H,98,112)(H3,85,91,116)(H2,99,100,104,117)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+,68+/m1/s1
|
||||
InChIKey |
MEUCPCLKGZSHTA-XYAYPHGZSA-N
|
||||
CAS Number |
CAS 214766-78-6
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
SuperDrug ATC ID |
L02BX02
|
||||
Target and Pathway | |||||
Target(s) | Gonadotropin-releasing hormone receptor | Target Info | Inhibitor | [527646] | |
NetPath Pathway | IL1 Signaling Pathway | ||||
IL2 Signaling Pathway | |||||
References | |||||
Ref 523763 | ClinicalTrials.gov (NCT01512472) Firmagon (Degarelix) Intermittent Therapy. U.S. National Institutes of Health. | ||||
Ref 540953 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5585). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.